Abstract
Background. In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial con-sortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS). Methods. Data from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS. Results. A log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status. Conclusion. Postsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1240-1250 |
| Number of pages | 11 |
| Journal | Neuro-Oncology |
| Volume | 20 |
| Issue number | 9 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
Keywords
- Bevacizumab
- Clinical trials
- Contrast-enhancing tumor volume
- GBM
- New glioblastoma
- Prognosis
- T1 subtraction
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
- Cancer Research
Cite this
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. / Ellingson, Benjamin M.; Abrey, Lauren E.; Nelson, Sarah J.; Kaufmann, Timothy J; Garcia, Josep; Chinot, Olivier; Saran, Frank; Nishikawa, Ryo; Henriksson, Roger; Mason, Warren P.; Wick, Wolfgang; Butowski, Nicholas; Ligon, Keith L.; Gerstner, Elizabeth R.; Colman, Howard; De Groot, John; Chang, Susan; Mellinghoff, Ingo; Young, Robert J.; Alexander, Brian M.; Colen, Rivka; Taylor, Jennie W.; Arrillaga-Romany, Isabel; Mehta, Arnav; Huang, Raymond Y.; Pope, Whitney B.; Reardon, David; Batchelor, Tracy; Prados, Michael; Galanis, Evanthia; Wen, Patrick Y.; Cloughesy, Timothy F.
In: Neuro-Oncology, Vol. 20, No. 9, 01.01.2018, p. 1240-1250.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
AU - Ellingson, Benjamin M.
AU - Abrey, Lauren E.
AU - Nelson, Sarah J.
AU - Kaufmann, Timothy J
AU - Garcia, Josep
AU - Chinot, Olivier
AU - Saran, Frank
AU - Nishikawa, Ryo
AU - Henriksson, Roger
AU - Mason, Warren P.
AU - Wick, Wolfgang
AU - Butowski, Nicholas
AU - Ligon, Keith L.
AU - Gerstner, Elizabeth R.
AU - Colman, Howard
AU - De Groot, John
AU - Chang, Susan
AU - Mellinghoff, Ingo
AU - Young, Robert J.
AU - Alexander, Brian M.
AU - Colen, Rivka
AU - Taylor, Jennie W.
AU - Arrillaga-Romany, Isabel
AU - Mehta, Arnav
AU - Huang, Raymond Y.
AU - Pope, Whitney B.
AU - Reardon, David
AU - Batchelor, Tracy
AU - Prados, Michael
AU - Galanis, Evanthia
AU - Wen, Patrick Y.
AU - Cloughesy, Timothy F.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background. In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial con-sortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS). Methods. Data from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS. Results. A log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status. Conclusion. Postsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy.
AB - Background. In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial con-sortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS). Methods. Data from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS. Results. A log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status. Conclusion. Postsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy.
KW - Bevacizumab
KW - Clinical trials
KW - Contrast-enhancing tumor volume
KW - GBM
KW - New glioblastoma
KW - Prognosis
KW - T1 subtraction
UR - http://www.scopus.com/inward/record.url?scp=85055446413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055446413&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noy053
DO - 10.1093/neuonc/noy053
M3 - Article
C2 - 29660006
AN - SCOPUS:85055446413
VL - 20
SP - 1240
EP - 1250
JO - Neuro-Oncology
JF - Neuro-Oncology
SN - 1522-8517
IS - 9
ER -